<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Bras Pneumol</journal-id>
      <journal-id journal-id-type="iso-abbrev">J Bras Pneumol</journal-id>
      <journal-title-group>
        <journal-title>Jornal Brasileiro de Pneumologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1806-3713</issn>
      <issn pub-type="epub">1806-3756</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Pneumologia e Tisiologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26176526</article-id>
      <article-id pub-id-type="pmc">4541764</article-id>
      <article-id pub-id-type="doi">10.1590/S1806-37132015000004553</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Series</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Use of sirolimus in the treatment of lymphangioleiomyomatosis: favorable responses in patients with different extrapulmonary manifestations<xref ref-type="fn" rid="fn01">*</xref>
</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Freitas</surname>
            <given-names>Carolina Salim Gon&#xE7;alves</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Baldi</surname>
            <given-names>Bruno Guedes</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ara&#xFA;jo</surname>
            <given-names>Mariana Sponholz</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Heiden</surname>
            <given-names>Glaucia Itamaro</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kairalla</surname>
            <given-names>Ronaldo Adib</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Carvalho</surname>
            <given-names>Carlos Roberto Ribeiro</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>1.</label>Collaborating Physician. Department of Pulmonology, Instituto do Cora&#xE7;&#xE3;o - InCor, Heart Institute - University of S&#xE3;o Paulo School of Medicine Hospital das Cl&#xED;nicas, S&#xE3;o Paulo, Brazil</aff>
      <aff id="aff2"><label>2.</label>Attending Physician. Department of Pulmonology, Instituto do Cora&#xE7;&#xE3;o - InCor, Heart Institute - University of S&#xE3;o Paulo School of Medicine Hospital das Cl&#xED;nicas, S&#xE3;o Paulo, Brazil</aff>
      <aff id="aff3"><label>3.</label>Associate Professor. Department of Pulmonology, Instituto do Cora&#xE7;&#xE3;o - InCor, Heart Institute - University of S&#xE3;o Paulo School of Medicine Hospital das Cl&#xED;nicas, S&#xE3;o Paulo, Brazil</aff>
      <aff id="aff4"><label>4.</label>Full Professor. Department of Pulmonology, Instituto do Cora&#xE7;&#xE3;o - InCor, Heart Institute - University of S&#xE3;o Paulo School of Medicine Hospital das Cl&#xED;nicas, S&#xE3;o Paulo, Brazil</aff>
      <author-notes>
        <corresp id="c01"><bold>Correspondence to:</bold> Carolina Salim Gon&#xE7;alves Freitas. Divis&#xE3;o de Pneumologia, Instituto do Cora&#xE7;&#xE3;o - InCor - Hospital das Cl&#xED;nicas da Faculdade de Medicina da Universidade de S&#xE3;o Paulo, Avenida Dr. En&#xE9;as de Carvalho Aguiar, 44, 8<sup>o</sup> andar, bloco 2, CEP 05403-900, S&#xE3;o Paulo, SP, Brasil. Tel. 55 11 2661-5191. Fax: 55 11 2661-5695. E-mail: <email>carolinasalim@gmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>May-Jun</season>
        <year>2015</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>May-Jun</season>
        <year>2015</year>
      </pub-date>
      <volume>41</volume>
      <issue>3</issue>
      <fpage>275</fpage>
      <lpage>280</lpage>
      <history>
        <date date-type="received">
          <day>13</day>
          <month>1</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>08</day>
          <month>4</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <sec>
          <title>OBJECTIVE:</title>
          <p> Lymphangioleiomyomatosis (LAM) is a rare disease that is currently considered a low-grade neoplasm with metastatic potential and variable progression. Mammalian target of rapamycin (mTOR) inhibitors, such as sirolimus and everolimus, have recently become a treatment option for LAM patients, especially those with extrapulmonary manifestations. The objective of the present study was to describe a case series of four patients with LAM in Brazil who showed significant improvement, particularly in their extrapulmonary manifestations, after treatment with sirolimus (at 1-4 mg/day). </p>
        </sec>
        <sec>
          <title>METHODS:</title>
          <p> We describe four cases of LAM patients with different extrapulmonary manifestations who were treated with sirolimus. </p>
        </sec>
        <sec>
          <title>RESULTS:</title>
          <p> After treatment with sirolimus for 12 months, one patient presented resolution of severe chylothorax; one had a significant reduction in renal angiomyolipoma volume; and one showed significant regression of retroperitoneal lymphangioleiomyomas and abdominal lymph node enlargement. After treatment with sirolimus for 6 months, the remaining patient had a significant reduction in the volume of a massive retroperitoneal lymphangioleiomyoma. </p>
        </sec>
        <sec>
          <title>CONCLUSIONS:</title>
          <p> Our findings confirm that mTOR inhibitors are beneficial for patients with LAM, especially those with extrapulmonary manifestations, such as renal angiomyolipoma, lymphangioleiomyomas, and chylous effusions. However, certain aspects, such as the optimal dose, duration of treatment, and long-term adverse effects, have yet to be sufficiently clarified for mTOR inhibitors to be incorporated into LAM management protocols. </p>
        </sec>
      </abstract>
      <kwd-group>
        <kwd>Neoplasms</kwd>
        <kwd>Lymphangioleiomyomatosis/therapy</kwd>
        <kwd>TOR serine-threonine kinases</kwd>
        <kwd>Sirolimus</kwd>
      </kwd-group>
      <counts>
        <fig-count count="8"/>
        <table-count count="2"/>
        <equation-count count="0"/>
        <ref-count count="24"/>
        <page-count count="6"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>Introduction</title>
      <p>Lymphangioleiomyomatosis (LAM) is a rare disease of unknown etiology. It primarily affects women of childbearing age, and the prevalence of LAM is approximately 1/1,000,000 population. It can occur in isolation or in association with tuberous sclerosis complex (TSC).<sup>(</sup>
<xref rid="B01" ref-type="bibr">1</xref>
<sup>-</sup>
<xref rid="B03" ref-type="bibr">3</xref>
<sup>)</sup> The disease is characterized by proliferation of atypical cells (LAM cells) with characteristics of low-grade neoplasm and metastatic potential, leading to vascular and bronchial obstruction and cyst formation.<sup>(</sup>
<xref rid="B04" ref-type="bibr">4</xref>
<sup>-</sup>
<xref rid="B08" ref-type="bibr">8</xref>
<sup>)</sup>
</p>
      <p>Major clinical manifestations of LAM include progressive dyspnea on exertion, dry cough, recurrent spontaneous pneumothorax, chylothorax, and hemoptysis.<sup>(</sup>
<xref rid="B01" ref-type="bibr">1</xref>
<sup>,</sup>
<xref rid="B03" ref-type="bibr">3</xref>
<sup>,</sup>
<xref rid="B09" ref-type="bibr">9</xref>
<sup>)</sup> Renal angiomyolipomas and lymphangioleiomyomas can occur. A CT scan of the chest typically shows the presence of diffuse, well-defined, thin-walled lung cysts. Although pulmonary function test results can be normal, variable and progressive lung function decline can occur over time. Reduced DLCO is the most common change, and spirometry most commonly reveals airflow obstruction and air trapping; bronchodilator test results can be positive in up to 25% of cases.<sup>(</sup>
<xref rid="B10" ref-type="bibr">10</xref>
<sup>-</sup>
<xref rid="B12" ref-type="bibr">12</xref>
<sup>)</sup>
</p>
      <p>A definitive diagnosis of LAM is based on the following<sup>(</sup>
<xref rid="B03" ref-type="bibr">3</xref>
<sup>,</sup>
<xref rid="B06" ref-type="bibr">6</xref>
<sup>)</sup>: </p>
      <p>
<list list-type="bullet"><list-item><p>typical chest HRCT findings, i.e., diffuse, well-defined lung cysts, in association with renal angiomyolipoma, pleural effusion/chylous ascites, lymphangioleiomyoma/lymph node involvement, or a definite or probable diagnosis of TSC</p></list-item><list-item><p>presence of lung cysts consistent with LAM on chest HRCT scans and pathological findings of LAM in a lung tissue sample preferably obtained by surgical biopsy</p></list-item></list>
</p>
      <p>Determination of serum levels of VEGF-D, which is a marker of lymphangiogenesis, has been increasingly used in order to aid in the diagnosis of LAM and to evaluate disease progression. Chest CT findings consistent with LAM associated with elevated VEGF-D levels are currently considered to be sufficient for the diagnosis of LAM.<sup>(</sup>
<xref rid="B13" ref-type="bibr">13</xref>
<sup>,</sup>
<xref rid="B14" ref-type="bibr">14</xref>
<sup>)</sup>
</p>
      <p>The progression of LAM is highly variable, ranging from asymptomatic patients to patients with progressive respiratory failure requiring lung transplantation. Survival has been shown to be better in recent studies than in previous studies; a recent study conducted in Brazil showed a five-year survival of 90%.<sup>(</sup>
<xref rid="B15" ref-type="bibr">15</xref>
<sup>)</sup>
</p>
      <p>Various drugs have been used in an attempt to control LAM. Matrix metalloproteinase inhibitors, such as doxycycline, and hormonal blockade have yielded controversial results and are not recommended for the treatment of LAM.<sup>(</sup>
<xref rid="B16" ref-type="bibr">16</xref>
<sup>-</sup>
<xref rid="B19" ref-type="bibr">19</xref>
<sup>)</sup> Mammalian target of rapamycin (mTOR) inhibitors, such as sirolimus and everolimus, are promising in the treatment of LAM, particularly in improving extrapulmonary manifestations and stabilizing or even improving lung function.<sup>(</sup>
<xref rid="B20" ref-type="bibr">20</xref>
<sup>,</sup>
<xref rid="B21" ref-type="bibr">21</xref>
<sup>)</sup>
</p>
      <p>The objective of the present study was to describe a case series of patients with LAM in Brazil treated with sirolimus, which had positive effects, particularly on extrapulmonary manifestations. </p>
    </sec>
    <sec>
      <title>Case series</title>
      <p>Of a total of 10 patients with LAM treated with sirolimus at our center during the study period, we describe four cases of patients in whom the drug was primarily used because of extrapulmonary involvement. </p>
      <sec>
        <title>Case 1</title>
        <p>A 48-year-old smoker (with a smoking history of 15 pack-years) was admitted with a two-year history of dyspnea, which had worsened one week prior. She reported no other diseases. The patient reported that she had undergone oophorectomy nine years prior because of a benign tumor and right nephrectomy six months prior because of renal angiomyolipoma. She had no relevant exposure history. Physical examination revealed that the patient had lost weight, breath sounds being absent in the right hemithorax and her SpO<sub>2</sub> being 92% on room air. A chest X-ray showed a large right pleural effusion (<xref ref-type="fig" rid="f01">Figure 1</xref>). The patient underwent thoracentesis, and a diagnosis of chylothorax was established. A pulmonary function test performed after chest tube drainage showed an FVC of 3.12 L (100% of predicted), an FEV<sub>1</sub> of 1.95 L (75% of predicted), an FEV<sub>1</sub>/FVC ratio of 0.62, a TLC of 5.27 L (92% of predicted), and a DLCO of 15.41 mL/min/mmHg (65% of predicted; <xref ref-type="table" rid="t01">Table 1</xref>). A chest CT scan showed diffuse, well-defined lung cysts. Her dyspnea worsened, and she presented with difficult-to-manage chylothorax, with a high output from the chest tube despite treatment with total parenteral nutrition. A decision was made to treat her with sirolimus (at 1 mg/day). Resolution of the chylothorax and functional stability were observed after 12 months of treatment (<xref ref-type="fig" rid="f01">Figure 1</xref> and <xref ref-type="table" rid="t01">Table 1</xref>). </p>
        <p>
<fig id="f01" orientation="portrait" position="float"><label>Figure 1.</label><caption><title>Chest X-rays taken before treatment with sirolimus (in A) and after 12 months of treatment with the drug (in B), showing resolution of chylothorax.</title></caption><graphic xlink:href="1806-3713-jbpneu-41-03-00275-gf01"/></fig>
</p>
        <p>
<table-wrap id="t01" orientation="portrait" position="float"><label>Table 1.</label><caption><title>Pulmonary function test results before and after treatment with sirolimus.a</title></caption><table frame="hsides" rules="groups" style="border-top: 1px solid black; border-bottom: 1px solid black; width: 100%"><thead><tr><th rowspan="2" colspan="1">Case</th><th colspan="2" rowspan="1">FVC</th><th colspan="2" rowspan="1">FEV<sub>1</sub>
</th><th colspan="2" rowspan="1">DLCO</th></tr><tr><th rowspan="1" colspan="1">pre-treatment</th><th rowspan="1" colspan="1">post-treatment</th><th rowspan="1" colspan="1">pre-treatment</th><th rowspan="1" colspan="1">post-treatment</th><th rowspan="1" colspan="1">pre-treatment</th><th rowspan="1" colspan="1">post-treatment</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">3.12 (100)</td><td rowspan="1" colspan="1">3.22 (103)</td><td rowspan="1" colspan="1">1.95 (75)</td><td rowspan="1" colspan="1">2.0 (77)</td><td rowspan="1" colspan="1">15.41 (65)<sup>b</sup>
</td><td rowspan="1" colspan="1">17.54 (74)<sup>b</sup>
</td></tr><tr><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">2.36 (61)</td><td rowspan="1" colspan="1">3.53 (91)</td><td rowspan="1" colspan="1">1.49 (46)</td><td rowspan="1" colspan="1">2.02 (62)</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">3.96 (90)</td><td rowspan="1" colspan="1">3.92 (89)</td><td rowspan="1" colspan="1">3.37 (89)</td><td rowspan="1" colspan="1">3.4 (90)</td><td rowspan="1" colspan="1">20.12 (98)<sup>b</sup>
</td><td rowspan="1" colspan="1">20.4 (99)<sup>b</sup>
</td></tr></tbody></table><table-wrap-foot><fn id="TFN02"><p>aValues expressed as L (% of predicted), except where otherwise indicated. bValues expressed as mL/min/mmHg (% of predicted).</p></fn></table-wrap-foot></table-wrap>
</p>
      </sec>
      <sec>
        <title>Case 2</title>
        <p>A 25-year-old patient diagnosed with LAM and TSC presented with a two-year history of recurrent pneumothorax and pleurodesis. She reported no smoking and had no relevant exposure history. Because of the neurological impairment associated with TSC, the patient had frequent convulsive seizures and a cognitive deficit. She also had large bilateral renal angiomyolipomas and had previously undergone a right partial nephrectomy because of hemorrhage. She had been using goserelin and doxycycline since 2010, and the renal tumor had progressively increased in the last two years. A decision was made to treat her with sirolimus, initially at 6 mg/day and subsequently at 2 mg/day because of nausea and vomiting. After 12 months of treatment, there was a significant reduction in the size of the angiomyolipoma (from approximately 20 cm, with confluent masses, to approximately 3 cm; <xref ref-type="fig" rid="f02">Figure 2</xref>). Because of her cognitive deficit, the patient did not undergo pulmonary function testing. </p>
        <p>
<fig id="f02" orientation="portrait" position="float"><label>Figure 2.</label><caption><title>Abdominal CT scans taken before treatment with sirolimus (in A) and after 12 months of treatment with the drug (in B), showing a reduction in bilateral renal angiomyolipoma volume.</title></caption><graphic xlink:href="1806-3713-jbpneu-41-03-00275-gf02"/></fig>
</p>
      </sec>
      <sec>
        <title>Case 3</title>
        <p>A 26-year-old nonsmoker with a three-year history of dyspnea on exertion presented with acute worsening of dyspnea. Although a large chylothorax was identified in 2011, it was not investigated at the time. One year later, the patient was admitted for investigation. Chest and abdominal CT scans showed diffuse cysts in the lung parenchyma, as well as large retroperitoneal lymphangioleiomyomas and abdominal lymph node enlargement. A diagnosis of LAM was established, and initial pulmonary function test results were as follows: FVC, 2.36 L (61% of predicted); FEV<sub>1</sub>, 1.49 L (46% of predicted); and FEV<sub>1</sub>/FVC, 0.63. The patient was started on sirolimus (at 2 mg/day) and after 12 months of treatment with the drug showed significant regression of the retroperitoneal and abdominal masses (<xref ref-type="fig" rid="f03">Figure 3</xref>), as well as improved lung function (<xref ref-type="table" rid="t01">Table 1</xref>). </p>
        <p>
<fig id="f03" orientation="portrait" position="float"><label>Figure 3.</label><caption><title>Abdominal CT scans taken before treatment with sirolimus (in A) and after 12 months of treatment with the drug (in B), showing a significant reduction in retroperitoneal lymphangioleiomyoma volume (white arrow).</title></caption><graphic xlink:href="1806-3713-jbpneu-41-03-00275-gf03"/></fig>
</p>
      </sec>
      <sec>
        <title>Case 4</title>
        <p>A 37-year-old nonsmoker presented with diffuse abdominal pain. The patient had no respiratory symptoms, relevant exposure history, or associated diseases. During the investigation, a large, heterogeneous retroperitoneal mass of approximately 18 cm in size was identified. A biopsy was performed, and the mass was diagnosed as a lymphangioleiomyoma. A chest CT scan showed diffuse cysts in the lung parenchyma, whereas pulmonary function test results, including DLCO, were normal (<xref ref-type="table" rid="t01">Table 1</xref>). The patient was started on sirolimus (at 2 mg/day) because of the size of the mass, which was symptomatic and posed a risk of hemorrhage. After 6 months of treatment with the drug, there was a significant reduction in lymphangioleiomyoma volume (<xref ref-type="fig" rid="f04">Figure 4</xref>). </p>
        <p>
<fig id="f04" orientation="portrait" position="float"><label>Figure 4.</label><caption><title>Abdominal CT scans taken before treatment with sirolimus (in A) and after 6 months of treatment with the drug (in B), showing resolution of an abdominal lymphangioleiomyoma (white arrow).</title></caption><graphic xlink:href="1806-3713-jbpneu-41-03-00275-gf04"/></fig>
</p>
      </sec>
    </sec>
    <sec sec-type="discussion">
      <title>Discussion</title>
      <p>In the four cases of patients with LAM described above, the use of sirolimus (at 1-6 mg/day) had positive effects, particularly on extrapulmonary manifestations, including a reduction in renal angiomyolipoma volume, abdominal mass volume, and retroperitoneal mass volume, as well as resolution of chylothorax. </p>
      <p>On the basis of the various mechanisms involved in the pathophysiology of LAM, several drugs have been used in an attempt to control the disease. Although doxycycline blocks metalloproteinases, it is currently not recommended, because a recent randomized study showed that it had no effect on lung function.<sup>(</sup>
<xref rid="B16" ref-type="bibr">16</xref>
<sup>,</sup>
<xref rid="B17" ref-type="bibr">17</xref>
<sup>)</sup> Hormonal blockade with the use of progesterone and gonadotropin-releasing hormone analogs has yielded controversial results and is currently not recommended.<sup>(</sup>
<xref rid="B18" ref-type="bibr">18</xref>
<sup>,</sup>
<xref rid="B19" ref-type="bibr">19</xref>
<sup>)</sup>
</p>
      <p>Mutations in the <italic>TSC1</italic> and <italic>TSC2</italic> genes, which can be found in patients with LAM, are associated with deregulation and hyperactivation of the mTOR pathway, which controls protein synthesis and cell growth. Inhibitors of mTOR inhibit T-lymphocyte activation and proliferation in response to antigenic and cytokine stimulation, binding to the FKBP-12 protein to form an immunosuppressive complex. This complex binds to mTOR, an important regulatory kinase, inhibiting its activity and ultimately blocking cell proliferation. </p>
      <p>Recent evidence has shown that mTOR inhibitors are promising options for patients with LAM and can be used in cases of large renal angiomyolipomas and lymphangioleiomyomas, as well as in the control of chylothorax and chylous ascites; in addition, mTOR inhibitors have beneficial effects on lung function, particularly in patients with a rapid decline in respiratory capacity and mild to moderate airflow limitation,<sup>(</sup>
<xref rid="B20" ref-type="bibr">20</xref>
<sup>,</sup>
<xref rid="B22" ref-type="bibr">22</xref>
<sup>)</sup> as observed in our case series. </p>
      <p>Although the use of sirolimus in patients with LAM is promising, certain issues have yet to be clarified, including the need for determining serum levels of the drug (as is done in kidney or lung transplant recipients, for example), treatment duration, and long-term treatment safety. Recent studies have shown that it is possible to use sirolimus at lower doses in order to reduce adverse effects without compromising treatment efficacy. <sup>(</sup>
<xref rid="B23" ref-type="bibr">23</xref>
<sup>)</sup> Doses of 1-2 mg/day are habitually used; however, in cases of large renal angiomyolipomas, higher initial doses can be used. A study by Yao et al. showed that the favorable effects of sirolimus on lung function remained after long-term treatment (approximately three and a half years) and that although adverse effects are common, including hypercholesterolemia, increased respiratory tract infections, diarrhea, and stomatitis, as well as acne and other skin disorders, they are usually mild and do not result in treatment discontinuation.<sup>(</sup>
<xref rid="B24" ref-type="bibr">24</xref>
<sup>)</sup> However, the risk of recurrence after treatment discontinuation has yet to be determined. </p>
      <p>Inhibitors of mTOR have become an important treatment option for selected cases of patients with LAM, especially those with significant extrapulmonary manifestations, such as renal angiomyolipomas, lymphangioleiomyomas, and chylous effusions. However, certain issues (such as the optimal dose and duration of treatment) have yet to be investigated in prospective studies for mTOR inhibitors to be permanently incorporated into LAM management protocols. </p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn id="fn01" fn-type="supported-by">
        <label>*</label>
        <p>Study carried out in the Department of Pulmonology, <italic>Instituto do Cora&#xE7;&#xE3;o</italic> - InCor, Heart Institute - University of S&#xE3;o Paulo School of Medicine <italic>Hospital das Cl&#xED;nicas</italic>, S&#xE3;o Paulo, Brazil.</p>
      </fn>
      <fn fn-type="supported-by">
        <p>Financial support: None.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="B01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Glassberg</surname>
              <given-names>MK</given-names>
            </name>
          </person-group>
          <article-title>Lymphangioleiomyomatosis</article-title>
          <source>Clin Chest Med</source>
          <year>2004</year>
          <volume>25</volume>
          <issue>3</issue>
          <fpage>573</fpage>
          <lpage>82 vii</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ccm.2004.05.003</pub-id>
          <pub-id pub-id-type="pmid">15331193</pub-id>
        </element-citation>
      </ref>
      <ref id="B02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Johnson</surname>
              <given-names>SR</given-names>
            </name>
          </person-group>
          <article-title>Lymphangioleiomyomatosis</article-title>
          <source>Eur Respir J</source>
          <year>2006</year>
          <volume>27</volume>
          <issue>5</issue>
          <fpage>1056</fpage>
          <lpage>1065</lpage>
          <pub-id pub-id-type="pmid">16707400</pub-id>
        </element-citation>
      </ref>
      <ref id="B03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Johnson</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Cordier</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Lazor</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Cottin</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Costabel</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Harari</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis</article-title>
          <source>Eur Respir J</source>
          <year>2010</year>
          <volume>35</volume>
          <issue>1</issue>
          <fpage>14</fpage>
          <lpage>26</lpage>
          <pub-id pub-id-type="doi">10.1183/09031936.00076209</pub-id>
          <pub-id pub-id-type="pmid">20044458</pub-id>
        </element-citation>
      </ref>
      <ref id="B04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pacheco-Rodriguez</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Kristof</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Stevens</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Crooks</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Moss</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Giles</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Filley Lecture. Genetics and gene expression in lymphangioleiomyomatosis</article-title>
          <source>Chest</source>
          <year>2002</year>
          <volume>121</volume>
          <fpage>56S</fpage>
          <lpage>60S</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1378/chest.121.3_suppl.56S">http://dx.doi.org/10.1378/chest.121.3_suppl.56S</ext-link>
          <pub-id pub-id-type="pmid">11893686</pub-id>
        </element-citation>
      </ref>
      <ref id="B05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Matsui</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Beasley</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Nelson</surname>
              <given-names>WK</given-names>
            </name>
            <name>
              <surname>Barnes</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Bechtle</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Falk</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Prognostic significance of pulmonary lymphangioleiomyomatosis histologic score</article-title>
          <source>Am J Surg Pathol</source>
          <year>2001</year>
          <volume>25</volume>
          <issue>4</issue>
          <fpage>479</fpage>
          <lpage>484</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/00000478-200104000-00007">http://dx.doi.org/10.1097/00000478-200104000-00007</ext-link>
          <pub-id pub-id-type="pmid">11257622</pub-id>
        </element-citation>
      </ref>
      <ref id="B06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pallisa</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Sanz</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Roman</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Maj&#xF3;</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Andreu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>C&#xE1;ceres</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Lymphangioleiomyomatosis: pulmonary and abdominal findings with pathologic correlation</article-title>
          <source>Radiographics</source>
          <year>2002</year>
          <volume>22</volume>
          <issue>Spec No</issue>
          <fpage>S185</fpage>
          <lpage>S198</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1148/radiographics.22.suppl_1.g02oc13s185">http://dx.doi.org/10.1148/radiographics.22.suppl_1.g02oc13s185</ext-link>
          <pub-id pub-id-type="pmid">12376610</pub-id>
        </element-citation>
      </ref>
      <ref id="B07">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hayashi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Fleming</surname>
              <given-names>MV</given-names>
            </name>
            <name>
              <surname>Stetler-Stevenson</surname>
              <given-names>WG</given-names>
            </name>
            <name>
              <surname>Liotta</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Moss</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ferrans</surname>
              <given-names>VJ</given-names>
            </name>
          </person-group>
          <article-title>Immunohistochemical study of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in pulmonary lymphangioleiomyomatosis (LAM)</article-title>
          <source>Hum Pathol</source>
          <year>1997</year>
          <volume>28</volume>
          <issue>9</issue>
          <fpage>1071</fpage>
          <lpage>1078</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0046-8177(97)90061-7">http://dx.doi.org/10.1016/S0046-8177(97)90061-7</ext-link>
          <pub-id pub-id-type="pmid">9308732</pub-id>
        </element-citation>
      </ref>
      <ref id="B08">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McCormack</surname>
              <given-names>FX</given-names>
            </name>
            <name>
              <surname>Travis</surname>
              <given-names>WD</given-names>
            </name>
            <name>
              <surname>Colby</surname>
              <given-names>TV</given-names>
            </name>
            <name>
              <surname>Henske</surname>
              <given-names>EP</given-names>
            </name>
            <name>
              <surname>Moss</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Lymphangioleiomyomatosis: calling it what it is: a low grade, destructive, metastasizing neoplasm</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>2012</year>
          <volume>186</volume>
          <issue>12</issue>
          <fpage>1210</fpage>
          <lpage>1212</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1164/rccm.201205-0848OE">http://dx.doi.org/10.1164/rccm.201205-0848OE</ext-link>
          <pub-id pub-id-type="pmid">23250499</pub-id>
        </element-citation>
      </ref>
      <ref id="B09">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Almoosa</surname>
              <given-names>KF</given-names>
            </name>
            <name>
              <surname>Ryu</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Mendez</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Huggins</surname>
              <given-names>JT</given-names>
            </name>
            <name>
              <surname>Young</surname>
              <given-names>LR</given-names>
            </name>
            <name>
              <surname>Sullivan</surname>
              <given-names>EJ</given-names>
            </name>
          </person-group>
          <article-title>Management of pneumothorax in lymphangioleiomyomatosis: effects on recurrence and lung transplantation complications</article-title>
          <source>Chest</source>
          <year>2006</year>
          <volume>129</volume>
          <issue>5</issue>
          <fpage>1274</fpage>
          <lpage>1281</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1378/chest.129.5.1274">http://dx.doi.org/10.1378/chest.129.5.1274</ext-link>
          <pub-id pub-id-type="pmid">16685019</pub-id>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yen</surname>
              <given-names>KT</given-names>
            </name>
            <name>
              <surname>Putzke</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Staats</surname>
              <given-names>BA</given-names>
            </name>
            <name>
              <surname>Burger</surname>
              <given-names>CD</given-names>
            </name>
          </person-group>
          <article-title>The prevalence of acute response to bronchodilator in pulmonary lymphangioleiomyomatosis</article-title>
          <source>Respirology</source>
          <year>2005</year>
          <volume>10</volume>
          <issue>5</issue>
          <fpage>643</fpage>
          <lpage>648</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1440-1843.2005.00762.x">http://dx.doi.org/10.1111/j.1440-1843.2005.00762.x</ext-link>
          <pub-id pub-id-type="pmid">16268919</pub-id>
        </element-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Taveira-DaSilva</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Hedin</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Stylianou</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Travis</surname>
              <given-names>WD</given-names>
            </name>
            <name>
              <surname>Matsui</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ferrans</surname>
              <given-names>VJ</given-names>
            </name>
          </person-group>
          <article-title>Reversible airflow obstruction, proliferation of abnormal smooth muscle cells, and impairment of gas exchange as predictors of outcome in lymphangioleiomyomatosis</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>2001</year>
          <volume>164</volume>
          <issue>6</issue>
          <fpage>1072</fpage>
          <lpage>1076</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1164/ajrccm.164.6.2102125">http://dx.doi.org/10.1164/ajrccm.164.6.2102125</ext-link>
          <pub-id pub-id-type="pmid">11587999</pub-id>
        </element-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Baldi</surname>
              <given-names>BG</given-names>
            </name>
            <name>
              <surname>Albuquerque</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Pimenta</surname>
              <given-names>SP</given-names>
            </name>
            <name>
              <surname>Salge</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Kairalla</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Carvalho</surname>
              <given-names>CR</given-names>
            </name>
          </person-group>
          <article-title>Exercise performance and dynamic hyperinflation in lymphangioleiomyomatosis</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>2012</year>
          <volume>186</volume>
          <issue>4</issue>
          <fpage>341</fpage>
          <lpage>348</lpage>
          <pub-id pub-id-type="doi">10.1164/rccm.201203-0372OC</pub-id>
          <pub-id pub-id-type="pmid">22700863</pub-id>
        </element-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Glasgow</surname>
              <given-names>CG</given-names>
            </name>
            <name>
              <surname>Avila</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Stylianou</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Moss</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement</article-title>
          <source>Chest</source>
          <year>2009</year>
          <volume>135</volume>
          <issue>5</issue>
          <fpage>1293</fpage>
          <lpage>1300</lpage>
          <pub-id pub-id-type="doi">10.1378/chest.08-1160</pub-id>
          <pub-id pub-id-type="pmid">19420197</pub-id>
        </element-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Young</surname>
              <given-names>LR</given-names>
            </name>
            <name>
              <surname>Vandyke</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Gulleman</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Inoue</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>KK</given-names>
            </name>
            <name>
              <surname>Schmidt</surname>
              <given-names>LS</given-names>
            </name>
          </person-group>
          <article-title>Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases</article-title>
          <source>Chest</source>
          <year>2010</year>
          <volume>138</volume>
          <issue>3</issue>
          <fpage>674</fpage>
          <lpage>681</lpage>
          <pub-id pub-id-type="doi">10.1378/chest.10-0573</pub-id>
          <pub-id pub-id-type="pmid">20382711</pub-id>
        </element-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Baldi</surname>
              <given-names>BG</given-names>
            </name>
            <name>
              <surname>Freitas</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Araujo</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Dias</surname>
              <given-names>OM</given-names>
            </name>
            <name>
              <surname>Pereira</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Pimenta</surname>
              <given-names>SP</given-names>
            </name>
          </person-group>
          <article-title>Clinical course and characterisation of lymphangioleiomyomatosis in a Brazilian reference centre</article-title>
          <source>Sarcoidosis Vasc Diffuse Lung Dis</source>
          <year>2014</year>
          <volume>31</volume>
          <issue>2</issue>
          <fpage>129</fpage>
          <lpage>135</lpage>
          <pub-id pub-id-type="pmid">25078640</pub-id>
        </element-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chang</surname>
              <given-names>WY</given-names>
            </name>
            <name>
              <surname>Cane</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Kumaran</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lewis</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tattersfield</surname>
              <given-names>AE</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>SR</given-names>
            </name>
          </person-group>
          <article-title>A 2-year randomised placebo-controlled trial of doxycycline for lymphangioleiomyomatosis</article-title>
          <source>Eur Respir J</source>
          <year>2014</year>
          <volume>43</volume>
          <issue>4</issue>
          <fpage>1114</fpage>
          <lpage>1123</lpage>
          <pub-id pub-id-type="doi">10.1183/09031936.00167413</pub-id>
          <pub-id pub-id-type="pmid">24311763</pub-id>
        </element-citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pimenta</surname>
              <given-names>SP</given-names>
            </name>
            <name>
              <surname>Baldi</surname>
              <given-names>BG</given-names>
            </name>
            <name>
              <surname>Kairalla</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Carvalho</surname>
              <given-names>CR</given-names>
            </name>
          </person-group>
          <article-title>Doxycycline use in patients with lymphangioleiomyomatosis: biomarkers and pulmonary function response</article-title>
          <source>J Bras Pneumol</source>
          <year>2013</year>
          <volume>39</volume>
          <issue>1</issue>
          <fpage>5</fpage>
          <lpage>15</lpage>
          <pub-id pub-id-type="doi">10.1590/S1806-37132013000100002</pub-id>
          <pub-id pub-id-type="pmid">23503480</pub-id>
        </element-citation>
      </ref>
      <ref id="B18">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Baldi</surname>
              <given-names>BG</given-names>
            </name>
            <name>
              <surname>Medeiros</surname>
              <given-names>P</given-names>
              <suffix>Junior</suffix>
            </name>
            <name>
              <surname>Pimenta</surname>
              <given-names>SP</given-names>
            </name>
            <name>
              <surname>Lopes</surname>
              <given-names>RI</given-names>
            </name>
            <name>
              <surname>Kairalla</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Carvalho</surname>
              <given-names>CR</given-names>
            </name>
          </person-group>
          <article-title>Evolution of pulmonary function after treatment with goserelin in patients with lymphangioleiomyomatosis</article-title>
          <source>J Bras Pneumol</source>
          <year>2011</year>
          <volume>37</volume>
          <issue>3</issue>
          <fpage>375</fpage>
          <lpage>379</lpage>
          <pub-id pub-id-type="doi">10.1590/S1806-37132011000300015</pub-id>
          <pub-id pub-id-type="pmid">21755194</pub-id>
        </element-citation>
      </ref>
      <ref id="B19">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Harari</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Cassandro</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Chiodini</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Taveira-DaSilva</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Moss</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Effect of a gonadotrophin-releasing hormone analogue on lung function in lymphangioleiomyomatosis</article-title>
          <source>Chest</source>
          <year>2008</year>
          <volume>133</volume>
          <issue>2</issue>
          <fpage>448</fpage>
          <lpage>454</lpage>
          <pub-id pub-id-type="doi">10.1378/chest.07-2277</pub-id>
          <pub-id pub-id-type="pmid">18071009</pub-id>
        </element-citation>
      </ref>
      <ref id="B20">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McCormack</surname>
              <given-names>FX</given-names>
            </name>
            <name>
              <surname>Inoue</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Moss</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Singer</surname>
              <given-names>LG</given-names>
            </name>
            <name>
              <surname>Strange</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Nakata</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Efficacy and safety of sirolimus in lymphangioleiomyomatosis</article-title>
          <source>N Engl J Med</source>
          <year>2011</year>
          <volume>364</volume>
          <issue>17</issue>
          <fpage>1595</fpage>
          <lpage>1606</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa1100391</pub-id>
          <pub-id pub-id-type="pmid">21410393</pub-id>
        </element-citation>
      </ref>
      <ref id="B21">
        <label>21</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Taveira-DaSilva</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Hathaway</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Stylianou</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Moss</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus</article-title>
          <source>Ann Intern Med</source>
          <year>2011</year>
          <volume>154</volume>
          <issue>12</issue>
          <fpage>797</fpage>
          <lpage>805 W-292-3</lpage>
          <pub-id pub-id-type="pmid">21690594</pub-id>
        </element-citation>
      </ref>
      <ref id="B22">
        <label>22</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Neurohr</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Hoffmann</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Huppmann</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Herrera</surname>
              <given-names>VA</given-names>
            </name>
            <name>
              <surname>Ihle</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Leuschner</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Is sirolimus a therapeutic option for patients with progressive pulmonary lymphangioleiomyomatosis</article-title>
          <source>Respir Res</source>
          <year>2011</year>
          <volume>12</volume>
          <fpage>66</fpage>
          <lpage>66</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1465-9921-12-66">http://dx.doi.org/10.1186/1465-9921-12-66</ext-link>
          <pub-id pub-id-type="pmid">21600034</pub-id>
        </element-citation>
      </ref>
      <ref id="B23">
        <label>23</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ando</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kurihara</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kataoka</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Ueyama</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Togo</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sato</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Efficacy and safety of low-dose sirolimus for treatment of lymphangioleiomyomatosis</article-title>
          <source>Respir Investig</source>
          <year>2013</year>
          <volume>51</volume>
          <issue>3</issue>
          <fpage>175</fpage>
          <lpage>183</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.resinv.2013.03.002">http://dx.doi.org/10.1016/j.resinv.2013.03.002</ext-link>
        </element-citation>
      </ref>
      <ref id="B24">
        <label>24</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yao</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Taveira-DaSilva</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Julien-Williams</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Stylianou</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Moss</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Sustained effects of sirolimus on lung function and cystic lung lesions in lymphangioleiomyomatosis</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>2014</year>
          <volume>190</volume>
          <issue>11</issue>
          <fpage>1273</fpage>
          <lpage>1282</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1164/rccm.201405-0918OC">http://dx.doi.org/10.1164/rccm.201405-0918OC</ext-link>
          <pub-id pub-id-type="pmid">25329516</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article id="S01" article-type="translation" xml:lang="pt">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>S&#xC9;rie De Casos</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Uso de sirolimo no tratamento de linfangioleiomiomatose: resposta favor&#xE1;vel em pacientes com diferentes manifesta&#xE7;&#xF5;es extrapulmonares<xref ref-type="fn" rid="fn02">*</xref>
</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Freitas</surname>
            <given-names>Carolina Salim Gon&#xE7;alves</given-names>
          </name>
          <xref ref-type="aff" rid="aff5">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Baldi</surname>
            <given-names>Bruno Guedes</given-names>
          </name>
          <xref ref-type="aff" rid="aff6">
<sup>2</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ara&#xFA;jo</surname>
            <given-names>Mariana Sponholz</given-names>
          </name>
          <xref ref-type="aff" rid="aff5">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Heiden</surname>
            <given-names>Glaucia Itamaro</given-names>
          </name>
          <xref ref-type="aff" rid="aff5">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kairalla</surname>
            <given-names>Ronaldo Adib</given-names>
          </name>
          <xref ref-type="aff" rid="aff7">
<sup>3</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Carvalho</surname>
            <given-names>Carlos Roberto Ribeiro</given-names>
          </name>
          <xref ref-type="aff" rid="aff8">
<sup>4</sup>
</xref>
        </contrib>
      </contrib-group>
      <aff id="aff5"><label>1</label>M&#xE9;dica Colaboradora. Divis&#xE3;o de Pneumologia, Instituto do Cora&#xE7;&#xE3;o - InCor - Hospital das Cl&#xED;nicas da Faculdade de Medicina da Universidade de S&#xE3;o Paulo, S&#xE3;o Paulo (SP) Brasil</aff>
      <aff id="aff6"><label>2</label>M&#xE9;dico Assistente. Divis&#xE3;o de Pneumologia, Instituto do Cora&#xE7;&#xE3;o - InCor -Hospital das Cl&#xED;nicas da Faculdade de Medicina da Universidade de S&#xE3;o Paulo, S&#xE3;o Paulo (SP) Brasil</aff>
      <aff id="aff7"><label>3</label>Professor Associado. Divis&#xE3;o de Pneumologia, Instituto do Cora&#xE7;&#xE3;o - InCor - Hospital das Cl&#xED;nicas da Faculdade de Medicina da Universidade de S&#xE3;o Paulo, S&#xE3;o Paulo (SP) Brasil</aff>
      <aff id="aff8"><label>4</label>Professor Titular. Divis&#xE3;o de Pneumologia, Instituto do Cora&#xE7;&#xE3;o - InCor -Hospital das Cl&#xED;nicas da Faculdade de Medicina da Universidade de S&#xE3;o Paulo, S&#xE3;o Paulo (SP) Brasil</aff>
      <author-notes>
        <corresp id="c02"><bold>Endere&#xE7;o para correspond&#xEA;ncia:</bold> Carolina Salim Gon&#xE7;alves Freitas. Divis&#xE3;o de Pneumologia, Instituto do Cora&#xE7;&#xE3;o - InCor - Hospital das Cl&#xED;nicas da Faculdade de Medicina da Universidade de S&#xE3;o Paulo, Avenida Dr. En&#xE9;as de Carvalho Aguiar, 44, 8&#xBA; andar, bloco 2, CEP 05403-900, S&#xE3;o Paulo, SP, Brasil. Tel. 55 11 2661-5191. Fax: 55 11 2661-5695. E-mail: <email>carolinasalim@gmail.com</email></corresp>
      </author-notes>
      <abstract>
        <sec>
          <title>OBJETIVO:</title>
          <p>A linfangioleiomiomatose (LAM) &#xE9; uma doen&#xE7;a rara que &#xE9; atualmente considerada uma neoplasia de baixo grau com potencial metast&#xE1;tico e evolu&#xE7;&#xE3;o vari&#xE1;vel. Os inibidores de <italic>mammalian target of rapamycin</italic> (mTOR), como o sirolimo e o everolimo, recentemente se tornaram uma op&#xE7;&#xE3;o para o tratamento de pacientes com LAM, especialmente daqueles com manifesta&#xE7;&#xF5;es extrapulmonares. O objetivo deste estudo foi descrever quatro casos de pacientes com LAM no Brasil que apresentaram melhora, especialmente das manifesta&#xE7;&#xF5;es extrapulmonares, ap&#xF3;s tratamento com sirolimo (em doses de 1-4 mg/dia). </p>
        </sec>
        <sec>
          <title>M&#xC9;TODOS:</title>
          <p> Descrevemos quatro casos de pacientes com LAM e diferentes manifesta&#xE7;&#xF5;es extrapulmonares tratados com sirolimo. </p>
        </sec>
        <sec>
          <title>RESULTADOS:</title>
          <p> Ap&#xF3;s o tratamento com sirolimo por 12 meses, um paciente apresentou resolu&#xE7;&#xE3;o do quilot&#xF3;rax de dif&#xED;cil manejo, um paciente teve redu&#xE7;&#xE3;o significativa do volume do angiomiolipoma renal, e uma paciente apresentou regress&#xE3;o importante de linfangioleiomiomas retroperitoneais e linfonodomegalias abdominais. Ap&#xF3;s tratamento com sirolimo por 6 meses, um paciente apresentou redu&#xE7;&#xE3;o significativa de volumoso linfangioleiomioma retroperitoneal. </p>
        </sec>
        <sec>
          <title>CONCLUS&#xD5;ES:</title>
          <p> Nossos achados confirmam que os inibidores de mTOR s&#xE3;o ben&#xE9;ficos para pacientes com LAM, especialmente para aqueles com manifesta&#xE7;&#xF5;es extrapulmonares, tais como angiomiolipomas renais, linfangioleiomiomas e derrames de origem quilosa. Entretanto, alguns pontos, tais como a dose ideal, a dura&#xE7;&#xE3;o do tratamento e os efeitos adversos em longo prazo, ainda precisam ser esclarecidos para que os inibidores de mTOR possam ser incorporados na abordagem da LAM.</p>
        </sec>
      </abstract>
      <kwd-group>
        <kwd>Neoplasias</kwd>
        <kwd>Linfangioleiomiomatose</kwd>
        <kwd>Serina-treonina quinases TOR</kwd>
        <kwd>Sirolimo</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <sec>
        <title>Introdu&#xE7;&#xE3;o</title>
        <p>A linfangioleiomiomatose (LAM) &#xE9; uma doen&#xE7;a rara de etiologia indeterminada; acomete principalmente mulheres em idade reprodutiva, e sua preval&#xEA;ncia &#xE9; de cerca de 1/1.000.000 habitantes. A LAM pode ocorrer isoladamente ou com o complexo de esclerose tuberosa (CET). <sup>(</sup>
<xref rid="B01" ref-type="bibr">1</xref>
<sup>-</sup>
<xref rid="B03" ref-type="bibr">3</xref>
<sup>)</sup> A doen&#xE7;a &#xE9; caracterizada por prolifera&#xE7;&#xE3;o de c&#xE9;lulas at&#xED;picas (c&#xE9;lulas de LAM) que exibem caracter&#xED;sticas de neoplasia de baixo grau, com potencial metast&#xE1;tico, levando a obstru&#xE7;&#xE3;o vascular e br&#xF4;nquica e forma&#xE7;&#xE3;o de cistos.<sup>(</sup>
<xref rid="B04" ref-type="bibr">4</xref>
<sup>-</sup>
<xref rid="B08" ref-type="bibr">8</xref>
<sup>)</sup>
</p>
        <p>As principais manifesta&#xE7;&#xF5;es cl&#xED;nicas da LAM s&#xE3;o dispneia progressiva aos esfor&#xE7;os, tosse seca, pneumot&#xF3;rax espont&#xE2;neo recorrente, quilot&#xF3;rax e hemoptise.<sup>(</sup>
<xref rid="B01" ref-type="bibr">1</xref>
<sup>,</sup>
<xref rid="B03" ref-type="bibr">3</xref>
<sup>,</sup>
<xref rid="B09" ref-type="bibr">9</xref>
<sup>)</sup> Podem surgir angiomiolipomas renais e linfangioleiomiomas. Na TC de t&#xF3;rax, o achado caracter&#xED;stico &#xE9; a presen&#xE7;a de cistos pulmonares difusos com paredes regulares e finas. Embora os testes de fun&#xE7;&#xE3;o pulmonar possam ser normais, pode ocorrer decl&#xED;nio progressivo e vari&#xE1;vel da fun&#xE7;&#xE3;o pulmonar ao longo do tempo. Redu&#xE7;&#xE3;o da DLCO &#xE9; a altera&#xE7;&#xE3;o mais frequente e, na espirometria, mais comumente se observa padr&#xE3;o de obstru&#xE7;&#xE3;o ao fluxo a&#xE9;reo, al&#xE9;m de aprisionamento a&#xE9;reo, inclusive com possibilidade de resposta positiva ao teste de broncodilata&#xE7;&#xE3;o em at&#xE9; 25% dos casos.<sup>(</sup>
<xref rid="B10" ref-type="bibr">10</xref>
<sup>-</sup>
<xref rid="B12" ref-type="bibr">12</xref>
<sup>)</sup>
</p>
        <p>O diagn&#xF3;stico definitivo de LAM baseia-se no seguinte<sup>(</sup>
<xref rid="B03" ref-type="bibr">3</xref>
<sup>,</sup>
<xref rid="B06" ref-type="bibr">6</xref>
<sup>)</sup>: </p>
        <p>
<list list-type="bullet"><list-item><p>&#x2022; achados caracter&#xED;sticos na TCAR de t&#xF3;rax, ou seja, cistos pulmonares difusos e com paredes regulares, associados a angiomiolipoma renal, derrame pleural/ascite quilosa, linfangioleiomioma/envolvimento ganglionar ou diagn&#xF3;stico definitivo ou prov&#xE1;vel de CET </p></list-item><list-item><p>&#x2022; presen&#xE7;a de cistos pulmonares compat&#xED;veis com LAM na TCAR de t&#xF3;rax e achados patol&#xF3;gicos de LAM em amostra de tecido pulmonar obtida preferencialmente por meio de bi&#xF3;psia cir&#xFA;rgica </p></list-item></list>
</p>
        <p>A dosagem s&#xE9;rica de VEGF-D, um marcador de linfangiog&#xEA;nese, tem ganhado espa&#xE7;o no aux&#xED;lio ao diagn&#xF3;stico, bem como na avalia&#xE7;&#xE3;o da progress&#xE3;o da doen&#xE7;a. Atualmente, considera-se que achados de TC de t&#xF3;rax compat&#xED;veis com LAM associados &#xE0; eleva&#xE7;&#xE3;o do VEGF-D s&#xE3;o suficientes para o diagn&#xF3;stico da doen&#xE7;a.<sup>(</sup>
<xref rid="B13" ref-type="bibr">13</xref>
<sup>,</sup>
<xref rid="B14" ref-type="bibr">14</xref>
<sup>)</sup>
</p>
        <p>A evolu&#xE7;&#xE3;o da LAM &#xE9; bastante vari&#xE1;vel, indo desde pacientes assintom&#xE1;ticas at&#xE9; pacientes com insufici&#xEA;ncia respirat&#xF3;ria progressiva com necessidade de transplante pulmonar. A sobrevida em estudos recentes tem se mostrado melhor que a descrita previamente; um estudo recente conduzido em nosso meio demonstrou que ela chega a 90% em cinco anos.<sup>(</sup>
<xref rid="B15" ref-type="bibr">15</xref>
<sup>)</sup>
</p>
        <p>Diversos medicamentos j&#xE1; foram utilizados na tentativa de controlar a LAM. Os inibidores de metaloproteinases de matriz, tais como a doxiciclina, e o bloqueio hormonal apresentaram resultados controversos e n&#xE3;o s&#xE3;o recomendados para o tratamento da LAM.<sup>(</sup>
<xref rid="B16" ref-type="bibr">16</xref>
<sup>-</sup>
<xref rid="B19" ref-type="bibr">19</xref>
<sup>)</sup> Atualmente, os inibidores de <italic>mammalian target of rapamycin</italic> (mTOR, alvo da rapamicina em mam&#xED;feros), como o sirolimo e o everolimo, s&#xE3;o promissores no tratamento da LAM, especialmente na melhora das manifesta&#xE7;&#xF5;es extrapulmonares e na estabiliza&#xE7;&#xE3;o ou eventualmente na melhora da fun&#xE7;&#xE3;o pulmonar. <sup>(</sup>
<xref rid="B20" ref-type="bibr">20</xref>
<sup>,</sup>
<xref rid="B21" ref-type="bibr">21</xref>
<sup>)</sup>
</p>
        <p>O objetivo do presente estudo foi descrever uma s&#xE9;rie de casos de pacientes com LAM no Brasil que utilizaram sirolimo, com efeitos positivos especialmente nas manifesta&#xE7;&#xF5;es extrapulmonares. </p>
      </sec>
      <sec>
        <title>S&#xE9;rie de casos</title>
        <p>De um total de 10 pacientes com LAM em uso de sirolimo em nosso centro durante o estudo, descrevemos quatro casos de pacientes nos quais o medicamento foi utilizado fundamentalmente em virtude do acometimento extrapulmonar. </p>
        <sec>
          <title>Caso 1</title>
          <p>Uma paciente de 48 anos, tabagista (com carga tab&#xE1;gica de 15 anos-ma&#xE7;o) foi internada com hist&#xF3;ria de dispneia havia dois anos, com piora havia uma semana. Negava outras doen&#xE7;as. A paciente relatou que fora submetida a ooforectomia havia nove anos em virtude de um tumor benigno e a nefrectomia direita havia 6 meses em virtude de angiomiolipoma renal. N&#xE3;o apresentava hist&#xF3;ria de exposi&#xE7;&#xE3;o relevante. O exame f&#xED;sico revelou que a paciente estava emagrecida, com murm&#xFA;rio vesicular abolido em todo o hemit&#xF3;rax direito e SpO<sub>2</sub> de 92% em ar ambiente. A radiografia de t&#xF3;rax revelou derrame pleural volumoso &#xE0; direita (<xref ref-type="fig" rid="f05">Figura 1</xref>). A paciente foi submetida a toracocentese, confirmando-se o diagn&#xF3;stico de quilot&#xF3;rax. A prova de fun&#xE7;&#xE3;o pulmonar realizada ap&#xF3;s a drenagem revelou CVF de 3,12 l (100% do previsto), VEF<sub>1</sub> de 1,95 l (75% do previsto), VEF<sub>1</sub>/CVF de 0,62, CPT de 5,27 l (92% do previsto) e DLCO de 15,41 ml/min/mmHg (65% do previsto; <xref ref-type="table" rid="t02">Tabela 1</xref>). A TC de t&#xF3;rax revelou cistos pulmonares difusos com paredes regulares. A paciente apresentou piora da dispneia e quilot&#xF3;rax de dif&#xED;cil manejo, mantendo-se um alto d&#xE9;bito de drenagem a despeito do tratamento com nutri&#xE7;&#xE3;o parenteral total. Optou-se por iniciar tratamento com sirolimo (1 mg/dia). Observou-se resolu&#xE7;&#xE3;o do quilot&#xF3;rax e estabilidade funcional ap&#xF3;s 12 meses de tratamento (<xref ref-type="fig" rid="f05">Figura 1</xref> e <xref ref-type="table" rid="t02">Tabela 1</xref>). </p>
          <p>
<fig id="f05" orientation="portrait" position="float"><label>Figura 1.</label><caption><title>Radiografia de t&#xF3;rax antes do tratamento com sirolimo (em A) e ap&#xF3;s 12 meses de tratamento com o medicamento (em B), mostrando a resolu&#xE7;&#xE3;o do quilot&#xF3;rax.</title></caption><graphic xlink:href="1806-3713-jbpneu-41-03-00275-gf01-pt"/></fig>
</p>
          <p>
<table-wrap id="t02" orientation="portrait" position="float"><label>Tabela 1.</label><caption><title>Resultados da prova de fun&#xE7;&#xE3;o pulmonar antes e depois do tratamento com sirolimo.a</title></caption><table frame="hsides" rules="groups" style="border-top: 1px solid black; border-bottom: 1px solid black; width: 100%"><thead><tr><th rowspan="2" colspan="1">Caso</th><th colspan="2" rowspan="1">CVF</th><th colspan="2" rowspan="1">VEF<sub>1</sub>
</th><th colspan="2" rowspan="1">DLCO</th></tr><tr><th rowspan="1" colspan="1">pr&#xE9;-tratamento</th><th rowspan="1" colspan="1">p&#xF3;s-tratamento</th><th rowspan="1" colspan="1">pr&#xE9;-tratamento</th><th rowspan="1" colspan="1">p&#xF3;s-tratamento</th><th rowspan="1" colspan="1">pr&#xE9;-tratamento</th><th rowspan="1" colspan="1">p&#xF3;s-tratamento</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">3,12 (100)</td><td rowspan="1" colspan="1">3,22 (103)</td><td rowspan="1" colspan="1">1,95 (75)</td><td rowspan="1" colspan="1">2,0 (77)</td><td rowspan="1" colspan="1">15,41 (65)<sup>b</sup>
</td><td rowspan="1" colspan="1">17,54 (74)<sup>b</sup>
</td></tr><tr><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">2,36 (61)</td><td rowspan="1" colspan="1">3,53 (91)</td><td rowspan="1" colspan="1">1,49 (46)</td><td rowspan="1" colspan="1">2,02 (62)</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">3,96 (90)</td><td rowspan="1" colspan="1">3,92 (89)</td><td rowspan="1" colspan="1">3,37 (89)</td><td rowspan="1" colspan="1">3,4 (90)</td><td rowspan="1" colspan="1">20,12 (98)<sup>b</sup>
</td><td rowspan="1" colspan="1">20,4 (99)<sup>b</sup>
</td></tr></tbody></table><table-wrap-foot><fn id="TFN01"><p>aValores expressos em l (% do previsto), exceto onde indicado. bValores expressos em ml/min/mmHg (% do previsto).</p></fn></table-wrap-foot></table-wrap>
</p>
        </sec>
        <sec>
          <title>Caso 2</title>
          <p>Uma paciente de 25 anos, com diagn&#xF3;stico de LAM associada a CET, apresentava hist&#xF3;ria de pneumot&#xF3;rax de repeti&#xE7;&#xE3;o e pleurodese havia dois anos. Negava tabagismo e n&#xE3;o apresentava hist&#xF3;ria de exposi&#xE7;&#xE3;o relevante. Em virtude do acometimento neurol&#xF3;gico associado ao CET, a paciente apresentava crises convulsivas frequentes e d&#xE9;ficit cognitivo. Apresentava ainda angiomiolipoma renal bilateral de grande volume, al&#xE9;m de ter sido anteriormente submetida a nefrectomia parcial direita em virtude de hemorragia. A paciente usava goserelina e doxiciclina desde 2010 e apresentou aumento progressivo do tumor renal nos &#xFA;ltimos dois anos. Optou-se por iniciar tratamento com sirolimo, inicialmente na dose de 6 mg/dia, com posterior redu&#xE7;&#xE3;o para 2 mg/dia em virtude de n&#xE1;useas e v&#xF4;mitos. Ap&#xF3;s 12 meses, observou-se redu&#xE7;&#xE3;o significativa do tamanho do angiomiolipoma (de cerca de 20 cm, com massas confluentes, para cerca de 3 cm; <xref ref-type="fig" rid="f06">Figura 2</xref>). Em virtude do d&#xE9;ficit cognitivo, a paciente n&#xE3;o foi submetida a avalia&#xE7;&#xE3;o funcional pulmonar. </p>
          <p>
<fig id="f06" orientation="portrait" position="float"><label>Figura 2.</label><caption><title>TC de abdome antes do tratamento com sirolimo (em A) e ap&#xF3;s 12 meses de tratamento com o medicamento (em B), mostrando diminui&#xE7;&#xE3;o do volume dos angiomiolipomas renais bilaterais.</title></caption><graphic xlink:href="1806-3713-jbpneu-41-03-00275-gf02-pt"/></fig>
</p>
        </sec>
        <sec>
          <title>Caso 3 </title>
          <p>Uma paciente de 26 anos, n&#xE3;o tabagista, com dispneia aos esfor&#xE7;os havia tr&#xEA;s anos, apresentou piora aguda do quadro. Em 2011, foi identificado quilot&#xF3;rax volumoso, que n&#xE3;o foi investigado na &#xE9;poca. Ap&#xF3;s um ano, a paciente foi internada para investiga&#xE7;&#xE3;o. As TCs de t&#xF3;rax e de abdome evidenciaram cistos difusos no par&#xEA;nquima pulmonar, al&#xE9;m de volumosos linfangioleiomiomas retroperitoneais e linfonodomegalias abdominais. Confirmou-se o diagn&#xF3;stico de LAM, e a prova de fun&#xE7;&#xE3;o pulmonar inicial apresentou os seguintes resultados: CVF de 2,36 l (61% do previsto), VEF<sub>1</sub> de 1,49 l (46% do previsto) e VEF<sub>1</sub>/CVF de 0,63. Foi iniciado o tratamento com sirolimo (2 mg/dia) e, ap&#xF3;s 12 meses de tratamento, a paciente apresentou regress&#xE3;o significativa das massas retroperitoneais e abdominais (<xref ref-type="fig" rid="f07">Figura 3</xref>), al&#xE9;m de melhora da fun&#xE7;&#xE3;o pulmonar (<xref ref-type="table" rid="t02">Tabela 1</xref>). </p>
          <p>
<fig id="f07" orientation="portrait" position="float"><label>Figura 3.</label><caption><title>TC de abdome antes do tratamento com sirolimo (em A) e ap&#xF3;s 12 meses de tratamento com o medicamento (em B), mostrando diminui&#xE7;&#xE3;o importante do volume dos linfangioleiomiomas retroperitoneais (seta branca).</title></caption><graphic xlink:href="1806-3713-jbpneu-41-03-00275-gf03-pt"/></fig>
</p>
        </sec>
        <sec>
          <title>Caso 4</title>
          <p>Uma paciente de 37 anos, n&#xE3;o tabagista, apresentava dor abdominal difusa. A paciente n&#xE3;o apresentava sintomas respirat&#xF3;rios, hist&#xF3;ria de exposi&#xE7;&#xE3;o relevante ou doen&#xE7;as associadas. Durante a investiga&#xE7;&#xE3;o, foi identificada uma massa retroperitoneal volumosa e heterog&#xEA;nea, de aproximadamente 18 cm de extens&#xE3;o. Realizou-se bi&#xF3;psia da massa abdominal, confirmando-se o diagn&#xF3;stico de linfangioleiomioma. A TC de t&#xF3;rax evidenciou cistos esparsos no par&#xEA;nquima pulmonar, ao passo que os resultados da prova de fun&#xE7;&#xE3;o pulmonar, incluindo a DLCO, foram normais (<xref ref-type="table" rid="t02">Tabela 1</xref>). Foi iniciado o tratamento com sirolimo (2 mg/dia) devido &#xE0; extens&#xE3;o da massa abdominal, com sintomas e risco de hemorragia. Ap&#xF3;s 6 meses de uso do medicamento, houve diminui&#xE7;&#xE3;o significativa do volume do linfangioleiomioma (<xref ref-type="fig" rid="f08">Figura 4</xref>). </p>
          <p>
<fig id="f08" orientation="portrait" position="float"><label>Figura 4.</label><caption><title>TC de abdome antes do tratamento com sirolimo (em A) e ap&#xF3;s 6 meses de tratamento com o medicamento (em B), mostrando resolu&#xE7;&#xE3;o de linfangioleiomioma abdominal (seta branca).</title></caption><graphic xlink:href="1806-3713-jbpneu-41-03-00275-gf04-pt"/></fig>
</p>
        </sec>
      </sec>
      <sec>
        <title>Discuss&#xE3;o</title>
        <p>Nos quatro casos de pacientes com LAM descritos acima, o uso de sirolimo (1-6 mg/dia) teve efeitos positivos, especialmente nas manifesta&#xE7;&#xF5;es extrapulmonares, incluindo redu&#xE7;&#xE3;o do volume de angiomiolipomas renais, de massas abdominais e de massas retroperitoneais, al&#xE9;m de resolu&#xE7;&#xE3;o do quilot&#xF3;rax. </p>
        <p>V&#xE1;rios medicamentos j&#xE1; foram utilizados na tentativa de controlar a LAM, baseando-se nos diversos mecanismos envolvidos em sua fisiopatologia. A doxiciclina, apesar de sua a&#xE7;&#xE3;o no bloqueio de metaloproteinases, n&#xE3;o &#xE9; recomendada no momento, pois um estudo randomizado recente demonstrou aus&#xEA;ncia de efeito na fun&#xE7;&#xE3;o pulmonar.<sup>(</sup>
<xref rid="B16" ref-type="bibr">16</xref>
<sup>,</sup>
<xref rid="B17" ref-type="bibr">17</xref>
<sup>)</sup> O bloqueio hormonal, com a utiliza&#xE7;&#xE3;o de progesterona e an&#xE1;logos de horm&#xF4;nio liberador de gonadotrofina, apresentou resultados controversos e tamb&#xE9;m n&#xE3;o &#xE9; indicado no momento.<sup>(</sup>
<xref rid="B18" ref-type="bibr">18</xref>
<sup>,</sup>
<xref rid="B19" ref-type="bibr">19</xref>
<sup>)</sup>
</p>
        <p>A muta&#xE7;&#xE3;o dos genes <italic>TSC1</italic> e <italic>TSC2</italic>, observada na LAM, est&#xE1; associada a desregula&#xE7;&#xE3;o e hiperativa&#xE7;&#xE3;o da via do mTOR, que atua no controle da s&#xED;ntese proteica e do crescimento celular. Os inibidores de mTOR inibem a ativa&#xE7;&#xE3;o e a prolifera&#xE7;&#xE3;o de linf&#xF3;citos T, que ocorrem em resposta ao est&#xED;mulo de ant&#xED;genos e de citocinas, ligando-se &#xE0; prote&#xED;na FKBP-12 para formar um complexo imunossupressor. Esse complexo liga-se ao mTOR, uma quinase regulat&#xF3;ria importante, inibindo sua atividade, o que, em &#xFA;ltima an&#xE1;lise, bloqueia a prolifera&#xE7;&#xE3;o celular. </p>
        <p>Evid&#xEA;ncias recentes t&#xEA;m demonstrado que os inibidores de mTOR s&#xE3;o op&#xE7;&#xF5;es promissoras para pacientes com LAM e podem ser utilizados em casos de angiomiolipomas renais e linfangioleiomiomas de grande volume, bem como no controle do quilot&#xF3;rax e da ascite quilosa, al&#xE9;m de serem ben&#xE9;ficos para a fun&#xE7;&#xE3;o pulmonar, principalmente em pacientes com r&#xE1;pido decl&#xED;nio da capacidade respirat&#xF3;ria e com limita&#xE7;&#xE3;o do fluxo a&#xE9;reo n&#xE3;o grave,<sup>(</sup>
<xref rid="B20" ref-type="bibr">20</xref>
<sup>,</sup>
<xref rid="B22" ref-type="bibr">22</xref>
<sup>)</sup> como observado em nossa s&#xE9;rie de casos. </p>
        <p>Embora o uso de sirolimo em pacientes com LAM seja promissor, algumas quest&#xF5;es ainda n&#xE3;o est&#xE3;o plenamente definidas, tais como a necessidade de dosagem s&#xE9;rica da medica&#xE7;&#xE3;o (como ocorre em pacientes que receberam transplante renal ou pulmonar, por exemplo), o tempo de tratamento e sua seguran&#xE7;a em longo prazo. Estudos recentes demonstraram que &#xE9; poss&#xED;vel usar a droga em doses mais baixas, a fim de reduzir os efeitos adversos, sem comprometer a resposta favor&#xE1;vel.<sup>(</sup>
<xref rid="B23" ref-type="bibr">23</xref>
<sup>)</sup> Habitualmente, utilizam-se doses de 1 a 2 mg/dia; por&#xE9;m, em casos de angiomiolipomas renais volumosos, podem ser utilizadas doses iniciais maiores. Um estudo realizado por Yao et al. demonstrou que os efeitos favor&#xE1;veis do sirolimo na fun&#xE7;&#xE3;o pulmonar mantiveram-se ap&#xF3;s um per&#xED;odo prolongado de tratamento (cerca de tr&#xEA;s anos e meio) e que, embora sejam comuns os efeitos adversos, tais como hipercolesterolemia, aumento de infec&#xE7;&#xF5;es do trato respirat&#xF3;rio, diarreia, estomatite, acne e outras altera&#xE7;&#xF5;es cut&#xE2;neas, eles geralmente s&#xE3;o de leve intensidade e n&#xE3;o determinam a interrup&#xE7;&#xE3;o do tratamento.<sup>(</sup>
<xref rid="B24" ref-type="bibr">24</xref>
<sup>)</sup> Entretanto, ainda n&#xE3;o est&#xE1; completamente estabelecido o risco de recidiva da doen&#xE7;a ap&#xF3;s a suspens&#xE3;o da medica&#xE7;&#xE3;o. </p>
        <p>Os inibidores de mTOR tornaram-se uma op&#xE7;&#xE3;o terap&#xEA;utica importante em casos selecionados de LAM, especialmente em pacientes com manifesta&#xE7;&#xF5;es extrapulmonares significativas, como angiomiolipomas renais, linfangioleiomiomas e derrames de origem quilosa. Entretanto, alguns pontos (tais como a dose ideal e a dura&#xE7;&#xE3;o do tratamento) ainda precisam ser esclarecidos em estudos prospectivos futuros para que os inibidores de mTOR sejam definitivamente incorporados na abordagem da LAM. </p>
      </sec>
    </body>
    <back>
      <fn-group>
        <fn id="fn02" fn-type="other">
          <label>*</label>
          <p>Trabalho realizado na Divis&#xE3;o de Pneumologia, Instituto do Cora&#xE7;&#xE3;o - InCor - Hospital das Cl&#xED;nicas da Faculdade de Medicina da Universidade de S&#xE3;o Paulo, S&#xE3;o Paulo (SP) Brasil.</p>
        </fn>
        <fn id="fn03" fn-type="supported-by">
          <p>Apoio financeiro: Nenhum.</p>
        </fn>
      </fn-group>
    </back>
  </sub-article>
</article>
</pmc-articleset>
